Cyclacel Pharma (CYCC) Reports Q1 Loss of $0.09

Cyclacel Pharma (NASDAQ: CYCC) reported Q1 EPS of ($0.09), versus ($0.19) reported last year. Revenue for the quarter came in at $139 million, versus $512 million reported last year.

Based on current plans, the Company estimates that it has capital resources to reach beyond the final analysis of SEAMLESS and continue existing programs through the end of 2017.

For earnings history and earnings-related data on Cyclacel Pharma (CYCC) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• Jernigan Capital (JCAP) Tops Q2 EPS by 5c
• Companhia de Saneamento Básico do Estado de São Paulo - SABESP (SBS) Tops Q2 EPS by 24c